Skip to main content

Table 2 CHESS demographic data

From: The cost of severe haemophilia in Europe: the CHESS study

  Country      
France (N = 272) Germany (N = 194) Italy (N = 280) Spain (N = 218) UK (N = 321) CHESS (N = 1,285)
PSCs received (%) 199 (73%) 97 (50%) 123 (44%) 96 (44%) 37 (12%) 552 (43%)
Haemophilia subtype (%)
 A 202 (74%) 153 (79%) 219 (78%) 176 (81%) 246 (77%) 996 (78%)
 B 70 (26%) 41 (21%) 61 (22%) 42 (19%) 75 (23%) 289 (22%)
Age (mean (SD)) 36.3 (13.7) 31.1 (12.0) 38.9 (15.5) 36.0 (14.1) 36.0 (15.9) 35.9 (14.7)
Age categories (%)
 18–35 154 (57%) 135 (70%) 142 (51%) 123 (56%) 192 (60%) 746 (58%)
 36–59 95 (35%) 52 (27%) 100 (36%) 78 (36%) 91 (28%) 416 (32%)
 60+ 23 (8%) 7 (4%) 38 (14%) 17 (8%) 38 (12%) 123 (10%)
Treatment strategy: Prophylaxis (%) 159 (58%) 117 (60%) 143 (51%) 143 (66%) 175 (55%) 737 (57%)
Inhibitor history (%)
 Never 225 (83%) 165 (85%) 233 (83%) 179 (82%) 289 (90%) 1,091 (85%)
 Previously 29 (11%) 25 (13%) 38 (14%) 27 (12%) 17 (5%) 136 (11%)
 Currently 18 (7%) 4 (2%) 9 (3%) 12 (6%) 15 (5%) 58 (5%)
Patients with coinfection (%)
 HIV 2 (1%) 4 (2%) 4 (1%) 9 (4%) 19 (6%) 38 (3%)
 HCV 7 (3%) 5 (3%) 22 (8%) 15 (7%) 21 (7%) 70 (5%)
EQ-5D-3 L index score (mean (SD)) 0.73 (0.30) 0.90 (0.12) 0.84 (0.12) 0.63 (0.37) 0.59 (0.36) 0.76 (0.28)